BioRestorative Therapies, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.1M
- Price
- $2.24
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.32%
- Volume
- 38.7K
About
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
Quick stats
Shares outstanding1.4M
Computed float1.2M
Float / shares84.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001505497
AI Summary
AI-generated1/15
majorbearishreverse split
BioRestorative Therapies Announces Reverse Stock Split
BioRestorative Therapies' board approved a 1-for-20 reverse stock split, effective 4:30 P.M. ET on September 7, 2026, with split-adjusted trading under the BRTX symbol beginning September 8 under a new CUSIP.
The stated purpose is regaining compliance with Nasdaq's $1.00 minimum bid price requirement for continued listing on the Capital Market under Listing Rule 5550(a)(2); no stockholder approval was required under Nevada law.
Shares outstanding drop from 27,622,556 to approximately 1,381,128, with authorized shares cut proportionately from 1.5 billion to 75 million; stockholder ownership percentages are unchanged apart from fractional shares being rounded up.
A 1-for-20 ratio is aggressive even by micro-cap standards and confirms the stock has been trading in Nasdaq deficiency territory; the release itself flags the risk that the split fails to hold the price above $1.00, that additional reverse splits are restricted within one year, and that the tiny post-split share count could threaten the minimum public float requirement.
Red flags
- 1-for-20 reverse split undertaken to regain Nasdaq $1.00 minimum bid price compliance -- listing deficiency signal
- Company discloses risk that split does not produce a sustained price above $1.00, which could trigger delisting proceedings
- Nasdaq rules restrict additional reverse splits within a one-year period, limiting further compliance tools
- Post-split share count of only ~1,381,128 shares creates severe liquidity and minimum-publicly-held-shares risk
- Micro-cap clinical-stage biotech with lead asset BRTX-100 still in Phase 2 -- no approved product revenue